Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.

Citation

• Lee, C., Davies, L., Marschner, I., Gebski, V., Lord, S., Di Leo, A., . . . De Souza, P. (2014). Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. Journal of Clinical Oncology, 32(15_suppl), 630. doi:10.1200/jco.2014.32.15_suppl.630

Digital Object Identifier (doi)

• 10.1200/jco.2014.32.15_suppl.630

Web Of Science Accession Number

Start Page

• 630

End Page

• 630

Volume

• 32

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2014

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Lee, C., Davies, L., Marschner, I., Gebski, V., Lord, S., Di Leo, A., . . . De Souza, P. (2014). Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. Journal of Clinical Oncology, 32(15_suppl), 630. doi:10.1200/jco.2014.32.15_suppl.630

Digital Object Identifier (doi)

• 10.1200/jco.2014.32.15_suppl.630

Web Of Science Accession Number

Start Page

• 630

End Page

• 630

Volume

• 32

Issue

• 15_suppl

Place Of Publication